CureGenetics, a biotechnology company focused on developing medicines and molecular diagnostics using gene editing technologies, has secured $17 million in Series A financing. Qiming Venture Partners led the round.
Source: Press Release
CureGenetics, a biotechnology company focused on developing medicines and molecular diagnostics using gene editing technologies, has secured $17 million in Series A financing. Qiming Venture Partners led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: